Title: Compositions and Methods for Topical Delivery of Oligonucleotides
Patent Number: 8,168,600
Filed: April 21, 2005
Lead Inventor: Sujatha Dokka, Isis Pharmaceuticals
The invention, the patent's abstract states, “relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.”
Title: Method of Delivering RNA Interference and Uses Thereof
Patent Number: 8,168,601
Filed: Aug. 15, 2005
Lead Inventor: Judy Lieberman, Harvard University
The invention, the patent's abstract states, relates to a “method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex.”
The fusion protein comprises “a targeting moiety, which will specifically bind to a site on a target cell, and a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell,” it adds.
Title: RNAi Inhibition of Alpha-ENaC Expression
Patent Number: 8,168,606
Filed: April 30, 2010
Lead Inventor: Gino Van Heeke, Novartis
“The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides,” the patent's abstract states.
Title: Methods of Treating Eye Diseases in Diabetic Patients
Patent Number: 8,168,607
Filed: June 7, 2010
Lead Inventor: Elena Feinstein, Quark Pharmaceuticals (Silence Therapeutics)
The invention, the patent's abstract states, provides “novel molecules, compositions, methods, and uses for treating microvascular disorders, eye diseases, and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.”
Title: RNAi-Mediated Inhibition of Rho Kinase for Treatment of Ocular Disorders
Patent Number: 8,168,609
Filed: Nov. 5, 2010
Lead Inventor: Jon Chatterton, Alcon
The patent, its abstract states, claims “RNA interference ... for [the] inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension, and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.”
Title: Control of Gene Expression
Patent Number: 8,168,774
Filed: Sept. 2, 2005
Lead Inventor: Michael Graham, Commonwealth Scientific and Industrial Research Organization
The invention relates to “a method of modifying gene expression and to synthetic genes for modifying [endogenous] gene expression in a cell, tissue, or organ of a transgenic organism, in particular a transgenic animal or plant,” according to the patent's abstract. “More particularly, the invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in tissue, organ, or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are cap repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced are also provided.”
Title: Compositions and Methods for Inhibiting Expression of Transthyretin
Patent Number: 8,168,775
Filed: Oct. 20, 2009
Lead Inventor: Dinah Sah, Alnylam Pharmaceuticals
“The invention relates to a double-stranded ribonucleic acid targeting a transthyretin gene, and methods of using the dsRNA to inhibit expression of TTR,” the patent's abstract states.
Title: Conjugates of Small Interfering Nucleic Acids
Application Number: 20120100096
Filed: Aug. 19, 2008
Lead Inventor: Samuel McManus, Nektar Therapeutics
The invention relates to “conjugates of small-interfering nucleic acids,” the patent application's abstract states. “Compositions of siNA suited for administration to a patient are described. Methods for delivering the compositions are also described.”
Title: Use of microRNAs to Control Virus Helper Nucleic Acids
Application Number: 20120100179
Filed: Nov. 25, 2009
Lead Inventor: Vernon Coffield, Alphavax
The invention, the patent application's abstract states, relates to “helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles are also provided.”
Title: Transducible Delivery of Nucleic Acids Using Modified dsRNA Binding Domains
Application Number: 20120101045
Filed: May 7, 2010
Lead Inventor: Steven Dowdy, University of California, Oakland
The invention comprises “fusion polypeptides and constructs useful in delivering anionically charged nucleic acid molecules including diagnostics and therapeutics to a cell or subject,” according to the patent application's abstract. “The fusion constructs include a protein transduction domain and a nucleic acid binding domain, or a protein transduction domain and a nucleic acid that is coated with one or more nucleic acid binding domains sufficient to neutralize an anionic charge on the nucleic acid. Also provided are methods of treating disease and disorders such as cell proliferative disorders.”
Title: Lipid Formulation
Application Number: 20120101148
Filed: Jan. 29, 2010
Lead Inventor: Akin Akinc, Alnylam Pharmaceuticals
“The invention features an improved lipid formulation comprising a cationic lipid of [a predefined] formula, a neutral lipid, a sterol, and a PEG or PEG-modified lipid,” the patent application's abstract states. “Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.”